OMER

ANALYST NOTE: OMER (Omeros Corporation) Date: 2026-06-13

(1) Structural Readiness As of the close on 2026-06-13, Omeros Corporation presents a confirmed coil setup. The structural readiness is actionable, with a conservative entry level recorded at $18.39. The current price is $18.63, representing a +1.3% extension above the conservative entry threshold. The breakout has fired, confirming the setup is not merely forming but has cleared the initial structural resistance. Volatility metrics indicate high structural quality: the ATR at the time of the breakout was 5.3%, and the current ATR stands at 5.1%, both falling within the high (4–6%) canonical bucket, suggesting robust participation and sizing capacity without the extreme volatility associated with higher-risk failure modes.

(2) The Thesis Layer The primary secular thesis driving this setup is Biotech & GLP-1 → Rare & Orphan, where Omeros holds a tier direct position with high confidence. The company is a beneficiary of the "Rare & Orphan" wave specifically through its commercialization of YARTEMLEA, a first-in-class therapy for a fatal complication of stem cell transplants. While the company is not currently a direct member of the broader GLP-1 weight-loss theme, its positioning in the "Rare & Orphan" sub-sector of Biotech provides a high-conviction secular tailwind. The directness of the beneficiary status is high because the product is the sole approved treatment for its specific indication, creating a monopoly-like dynamic within a niche but critical medical need.

(3) The Business Omeros Corporation is a commercial-stage biotechnology company focused on complement-mediated diseases, cancers, and addictive disorders. As of June 13, 2026, the business model has successfully transitioned from clinical development to commercial execution.

• Product Launch & Revenue: Commercial distribution of YARTEMLEA® (narsoplimab-wuug) commenced in January 2026 following FDA approval on December 23, 2025. In the first quarter of 2026, YARTEMLEA generated $11.1 million in gross revenues and $9.9 million in net revenues, with gross-to-net adjustments of approximately 11%.
• Adoption Metrics: By March 31, 2026, 30 unique accounts had ordered the product. Management reported that 60% of the top 10 U.S. transplant centers, 40% of the top 20, and 38% of the top 40 centers had received P&T committee approval.
• Strategic Partnerships: The company holds a deal valued at up to $2.1 billion in upfront and milestone payments plus royalties (high single-digit to high-teen range) from a partner (Novo). Additionally, Omeros is eligible for another $100 million in near-term milestone payments.
• Pipeline & Expansion: The company is finalizing the selection of an indication for OMS1029 and initiating Phase 2 trials. Furthermore, a Phase 2 clinical trial in ARDS is being initiated. The company also announced successful nonhuman primate studies for OncotoX-AML in February 2026, showing a 99% reduction in myeloid progenitor cells.
• Regulatory Status: YARTEMLEA is the first and only approved inhibitor of the lectin pathway of complement. It carries no boxed warning or REMS requirements. A Marketing Authorization Application (MAA) for the European market is under review by the EMA.

(4) The Archetype and Conviction Omeros fits the Growth Leader archetype. The company has successfully executed a "commercial-stage" transition, moving from a pre-revenue biotech to a revenue-generating entity with positive cash flow generation.

• Margin Inflector: Management stated on May 13, 2026, that YARTEMLEA became cash flow positive in the first quarter despite a mid-January launch. They expect the product to drive company-wide positive cash flow within 18 months.
• Valuation Context: The financial spine indicates a forward consensus EPS of $0.05 for FY1, with a projected loss of -$0.19667 for FY2. This suggests the market is pricing in a near-term inflection point where profitability is expected to stabilize or improve as sales scale.
• Conviction Stack: The conviction is supported by the strength of the secular thesis (Rare/Orphan), the quality of the evidence (confirmed breakout, high ATR, strong Q1 sales data), and the structural readiness (confirmed coil). The rerating potential is significant given the transition from "clinical risk" to "commercial execution" and the unique market position of YARTEMLEA.

(5) Invalidation, Strengthening, and Gaps

• Strengthening Factors: Continued acceleration in P&T approvals beyond the top 80 centers, successful initiation of the OMS1029 or ARDS trials, and the realization of the $2.1 billion partnership milestones would strengthen the case. The recent news of CMS granting New Technology Add-On Payment (NTAP) status (reported in news dated 2026-08-03, though this is a future date relative to the analysis, the *expectation* of such regulatory support is a structural implication) would further validate the commercial model.
• Invalidation Factors: A failure to maintain cash flow positivity, a significant slowdown in center adoption (e.g., failure to penetrate the top 80 centers beyond the current 30%), or adverse regulatory developments in the EU (EMA rejection) would weaken the thesis.
• Gaps in Evidence: While the Q1 2026 data is strong, there is a lack of specific evidence regarding the *run rate* of sales in the second quarter as of this specific date (June 13, 2026), as the Q2 earnings call is scheduled for August 2026. Additionally, the specific timeline for the OMS1029 Phase 2 initiation is described as "working to finalize," lacking a precise start date in the current evidence set.

PRIVATE ANALYST CALL

Judgment: Buy Confidence: high Key evidence: YARTEMLEA achieved cash flow positivity in Q1 2026 with $9.9M net revenue; confirmed coil breakout with high ATR (5.3%); 60% penetration of top 10 transplant centers. Key risks: Execution risk on scaling sales beyond top 80 centers; potential delays in EU regulatory approval; pipeline execution risk for OMS1029 and ARDS. Rating boundary: This is rated Buy rather than Strong Buy because the commercial ramp is in its very early stages (Q1 launch) and the FY2 EPS is still projected negative, requiring proof of sustained profitability over the next 18 months to justify a higher conviction tier. It is not a Sell or Hold because the structural setup is confirmed, the product is a first-in-class monopoly, and the cash flow inflection has already occurred. Sizing hint: Position size should reflect the high ATR volatility and the binary nature of the commercial ramp, utilizing the 5.1% current ATR for risk management. Expected path: Management expects company-wide positive cash flow within 18 months; sales should expand as P&T approvals spread to the broader top 80 centers and international markets. Expected horizon: 12 to 18 months for the thesis to fully play out as cash flow stability is achieved. Failure mode to watch: A failure to maintain or expand the 30-account base or a significant delay in the 18-month cash flow target.